Biopharma’s 2025 M&A boom: Dealmaking surges as patent pressures intensify
Propelled by a flurry of dealmaking late in the year, M&As in 2025 ended on a strong note, with high activity expected to continue in 2026.
deal
Real-time data: how to gain an edge amid clinical services consolidation
Pfizer clinches $10bn Metsera deal as Novo Nordisk retreats
Novo Nordisk locks horns with Pfizer in late bid for Metsera
Bavarian Nordic’s shareholders and board in standoff amid takeover offer
BioCryst to buy Astria Therapeutics for $700m in enterprise value
Roche signs agreement to acquire 89bio in $2.4bn deal
CapVest to buy control of generics giant Stada in €10bn deal
